Incorporating adverse event relatedness into dose-finding clinical trial designs

Decrease Font Size Increase Font Size Text Size Print This Page

Wiley:  10/7/13

Dose-finding designs estimate the dose level of a drug based on observed adverse events. Relatedness of the adverse event to the drug has been generally ignored in all proposed design methodologies. These designs assume that the adverse events observed during a trial are definitely related to the drug, which can lead to flawed dose-level estimation. We incorporate adverse event relatedness into the so-called continual reassessment method. Adverse events that have ‘doubtful’ or ‘possible’ relationships to the drug are modelled using a two-parameter logistic model with an additive probability mass. Adverse events ‘probably’ or ‘definitely’ related to the drug are modelled using a cumulative logistic model.  Read more

Share the Clinical Trial Engagement Network
 

 

National Minority Quality Forum
1201 15th Street, NW
Suite 340
Washington, DC 20005

 

Tel: 202.223.7560
Fax: 202.223.7567
www.nmqf.org

Terms of Use     l    Privacy Policy